Immune cells within tertiary lymphoid structures are associated with progression‐free survival in patients with locoregional recurrent breast cancer
Cancer Medicine · 2024
DOI: 10.1002/cam4.6864 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Jinyuan Gu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplasm Recurrence, Local, Tumor Microenvironment, Tertiary Lymphoid Structures. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Priority Academic Program Development of Jiangsu Higher Education Institutions, National Natural Science Foundation of China.
Abstract (Originalsprache)
Introduction
Locoregional recurrent breast cancers have a poor prognosis. Little is known about the prognostic impact of immune microenvironment, and tertiary lymphoid structures (TLSs) in particular have not been reported. Thus, we aimed to characterize the immune microenvironment in locoregional recurrent breast tumors and to investigate its relationship with prognosis.
Methods
We retrospectively included 112 patients with locoregional recurrent breast cancer, and hematoxylin–eosin staining and immunohistochemical staining (CD3, CD4, CD8, CD19, CD38, and CD68) were performed on locoregional recurrent tumor samples. The association of immune cells and TLSs with progression‐free survival (PFS) were analyzed by survival analysis.
Results
We found more immune cells in the peritumor than stroma. After grouping according to estrogen receptor (ER) status, a low level of peritumoral CD3+ cells in ER+ subgroup ( p = 0.015) and a low level of stromal CD68+ cells in ER− subgroup ( p = 0.047) were both associated with longer PFS. TLSs were present in 68% of recurrent tumors, and CD68+ cells within TLSs were significantly associated with PFS as an independent prognostic factor ( p = 0.035). TLSs and immune cells (CD3, CD38, and CD68) within TLSs were associated with longer PFS in ER− recurrent tumors ( p = 0.044, p = 0.012, p = 0.050, p < 0.001, respectively), whereas CD38+ cells within TLSs were associated with shorter PFS in ER+ recurrent tumors ( p = 0.037).
Conclusion
Our study proposes potential predictors for the clinical prognosis of patients with locoregional recurrent breast cancer, emphasizing the prognostic value of immune cells within TLSs, especially CD68+ cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
- Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center For Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China.
- Department of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
- Department of General Surgery, Sir Run Run Hospital, Nanjing Medical University, Nanjing, China.
- Pancreas Center & Department of General Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
- Pancreas Institute of Nanjing Medical University, Nanjing, Jiangsu, China.
ORCID-Profile: Yi Zhao, Kai Zhang, Shui Wang, Cong Wang, Wenbin Zhou
Förderung
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- National Natural Science Foundation of China
Zitieren
APA
Gu, J., Wang, J., Sun, Y., Mao, X., Qian, C., Tang, X., Wang, J., Xie, H., Ling, L., Zhao, Y., Liu, X., Zhang, K., Pan, H., Wang, S., Wang, C., & Zhou, W. (2024). Immune cells within tertiary lymphoid structures are associated with progression‐free survival in patients with locoregional recurrent breast cancer. Cancer Medicine. https://doi.org/10.1002/cam4.6864
Vancouver
Gu J, Wang J, Sun Y, Mao X, Qian C, Tang X, et al. Immune cells within tertiary lymphoid structures are associated with progression‐free survival in patients with locoregional recurrent breast cancer. Cancer Medicine. 2024. doi:10.1002/cam4.6864
BibTeX
@article{Gu2024,
author = {Gu, Jinyuan and Wang, Jiaming and Sun, Yue and Mao, Xinrui and Qian, Chao and Tang, Xinyu and Wang, Ji and Xie, Hui and Ling, Lijun and Zhao, Yi and Liu, Xiaoan and Zhang, Kai and Pan, Hong and Wang, Shui and Wang, Cong and Zhou, Wenbin},
title = {Immune cells within tertiary lymphoid structures are associated with progression‐free survival in patients with locoregional recurrent breast cancer},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.6864}
}
EUVIMED